Resverlogix to Begin Phase II Atherosclerosis Trial
Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease.
Read more »Researchers Identify Gene Linked to Childhood Asthma
U.S. researchers have identified a gene that is linked to childhood asthma.
Read more »Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
Read more »New Era Begins for NeoStem Following China Acquisition
NeoStem is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications.
Read more »Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
Read more »Possible Cause of Inflammatory Bowel Disease Uncovered
A researcher at the University of Adelaide found that people suffering from inflammatory bowel disease have a lower number of regulatory cells that control the immune system.
Read more »Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.
Read more »[Company Profile] MicroPhage
MicroPhage of Longmont, Colo., has developed a platform of rapid diagnostic tests to identify staph bacteria and determine methicillin resistance (MRSA) and susceptibility (MSSA).
Read more »